Could Cellect Biotechnology Ltd. (APOP) Decrease Even More? The Stock Formed Multiple Bottom

May 22, 2018 - By Louis Casey

The stock of Cellect Biotechnology Ltd. (APOP) shows a multiple bottoms pattern with $6.43 target or 9.00 % below today’s $7.06 share price. The 5 months chart pattern indicates high risk for the $45.97 million company. It was reported on May, 22 by Finviz.com. If the $6.43 price target is reached, the company will be worth $4.14 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 0.41% or $0.029 during the last trading session, reaching $7.061. About 5,960 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has declined 42.02% since May 22, 2017 and is downtrending. It has underperformed by 53.57% the S&P500.

Analysts await Cellect Biotechnology Ltd. (NASDAQ:APOP) to report earnings on June, 4. They expect $-0.30 EPS, down 650.00 % or $0.26 from last year’s $-0.04 per share. After $-0.16 actual EPS reported by Cellect Biotechnology Ltd. for the previous quarter, Wall Street now forecasts 87.50 % negative EPS growth.

More news for Cellect Biotechnology Ltd. (NASDAQ:APOP) were recently published by: Prnewswire.com, which released: “Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results” on May 17, 2018. Benzinga.com‘s article titled: “25 Stocks Moving In Tuesday’s Pre-Market Session” and published on May 22, 2018 is yet another important article.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $45.97 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.